Braveheart Bio, Inc. BRVE
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 4.76M | 4.14M | 27.00K | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 15.88M | 15.05M | 27.00K | ||
| Operating Income | -15.88M | -15.05M | -27.00K | ||
| Income Before Tax | -14.99M | -14.28M | -381.00K | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -14.99M | -14.28M | -381.00K | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -14.99M | -14.28M | -381.00K | ||
| EBIT | -15.88M | -15.05M | -27.00K | ||
| EBITDA | -15.88M | -15.05M | -- | ||
| EPS Basic | -2.51 | -2.08 | -0.14 | ||
| Normalized Basic EPS | -1.27 | -1.30 | -0.01 | ||
| EPS Diluted | -2.51 | -2.08 | -0.14 | ||
| Normalized Diluted EPS | -1.27 | -1.30 | -0.01 | ||
| Average Basic Shares Outstanding | 7.40M | 6.86M | 2.79M | ||
| Average Diluted Shares Outstanding | 7.40M | 6.86M | 2.79M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||